The AM General released more details of its deal to manufacture an estimated quantity of up to 2,800 new M997A3 High Mobility Multipurpose Wheeled Vehicle (HMMWV) Ambulances for U.S. Army.

According to the company, the AM General has been awarded orders worth $800 million from the U.S. Army to supply 2,800 new M997A3 HMMWVs in ambulance configuration.

“AM General continues to support the warfighter’s needs by delivering high-quality M997A3 ambulances based off our modernized, proven, rugged, all-terrain HMMWV’s,” said Chris Vanslager, AM General Executive Vice President, US Defense.  “We understand the importance of being able to reliably and safely transport the wounded within operational areas on the battlefield to medical aid stations and are proud that the M997A3 can fulfill this critical mission.”

As the prime contractor, and in partnership with Rock Island Arsenal, AM General will deliver quality and consistency in the M997A3 HMMWV ambulance manufacturing process by applying its Quality Management System across the entire enterprise which includes production parts suppliers, chassis and shelter production, and integrated vehicle testing. The Company will procure all system materials and parts, manufacture the chassis and body structure before shipping the integrated chassis system to Rock Island Arsenal where the ambulance shelter will be manufactured and assembled into the final product.

On the HMMWV platform designed M997A3 ambulance vehicle, which is equipped with advanced armor protection, these combat ambulances were built to reliably transport causalities from the battlefield to medical aid stations.

Capable of transporting up to four litter patients, eight ambulatory patients—or a combination of both—as well as medical personnel, equipment and a driver, the M997A3 is dependable in the face of danger.

As with all active vehicle programs, AMG General leverages its more than 100 years of automotive experience to deliver affordable quality products on time. The first M997A3 ambulance deliveries are scheduled for Q2 2019.